Strategies To Mitigate Common Pitfalls In Early Drug Development
Source: Catalent

Thousands of drug candidates are abandoned annually due to solubility and bioavailability issues, but advanced formulation technologies can profoundly impact how a drug compound is processed in the body and improve the fate of many of these candidates, improving pharmacokinetic profiles and pharmacodynamic responses. Two Catalent experts discuss the ways companies can address issues with low bioavailability, and the benefits of enlisting an experienced drug development partner.
Featured Experts:
Jan Neelissen, Ph.D., Scientific Advisor, Science & Technology, Catalent
Stephen Tindal, Director, Science & Technology, Catalent
VIEW THE Q&A!
Log In
Signing up provides unlimited access to:
Free Sign Up

Signing up provides unlimited access to:
- Trend and Leadership Articles
- Case Studies
- Extensive Product Database
- Premium Content
HELLO. PLEASE LOG IN.
X
Not yet a member of Outsourced Pharma? Register today.
ACCOUNT SIGN UP
X
Please fill in your account details
ACCOUNT SIGN UP
Catalent
This website uses cookies to ensure you get the best experience on our website. Learn more